← Back to Search

Ghrelin Receptor Agonist

anamorelin for Sarcopenia

Phase 1

Waitlist Available

Led By Bess Dawson-Hughes, MD

Research Sponsored by Tufts University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Ability to sign informed consent form

Community dwelling individuals aged 50 years and older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 12 months

Awards & highlights

Study Summary

This trial will test whether a ghrelin receptor agonist can improve short-term indicators of muscle and bone health in adults with low bone and muscle mass.

Eligible Conditions

Sarcopenia
Osteopenia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Total Body Muscle Mass

Secondary outcome measures

Alanine Transaminase (ALT)

Appendicular Lean Mass (ALM)

Fasting Plasma Glucose

+3 more

Other outcome measures

Bone Mineral Density of the Spine and Hip

Handgrip Strength

Health Aging and Body Composition-Physical Performance Battery

+3 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: anamorelinActive Control1 Intervention

one 100 mg tablet daily, taken one hour before breakfast

Group II: microcrystaline cellulosePlacebo Group1 Intervention

one identical appearing tablet daily, taken one hour before breakfast

0 / 7Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Tufts UniversityLead Sponsor

263 Previous Clinical Trials

661,742 Total Patients Enrolled

9 Trials studying Sarcopenia

692 Patients Enrolled for Sarcopenia

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH

483 Previous Clinical Trials

1,086,908 Total Patients Enrolled

2 Trials studying Sarcopenia

315 Patients Enrolled for Sarcopenia

Bess Dawson-Hughes, MDPrincipal InvestigatorTufts University

6 Previous Clinical Trials

785 Total Patients Enrolled

4 Trials studying Sarcopenia

318 Patients Enrolled for Sarcopenia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies remaining in this research endeavor for participants?

"At the current moment, no new participants are being accepted for this medical trial. It was first posted on December 5th 2019 and underwent last edits on February 4th 2022. For those looking to be enrolled in a similar study, there exist 139 studies recruiting patients with sarcopenia as well as 14 trials actively seeking anamorelin candidates."

Answered by AI

Have prior investigations been conducted on anamorelin?

"At this current time, 14 clinical trials assessing anamorelin are underway, 5 of which have reached Phase 3. Most studies pertaining to this medication occur in Deszk, New york; however there are 163 locations running such experiments globally."

Answered by AI

How many participants are currently taking part in this research program?

"This clinical trial has concluded its patient recruitment. Initially posted on December 5th 2019, the study was last edited on February 4th 2022. Presently, 139 trials related to sarcopenia and 14 studies focused on anamorelin are actively recruiting participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effect of a Ghrelin Receptor Agonist on Muscle and Bone

Bess Dawson-Hughes 2019. "Effect of a Ghrelin Receptor Agonist on Muscle and Bone". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04021706.